b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="immage" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2291031/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Safety and immunogenicity of an MF59\xe2\x84\xa2-adjuvanted subunit influenza vaccine in elderly Chinese subjects</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291031/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Immunity &amp; ageing : I &amp; A" /><meta name="citation_title" content="Safety and immunogenicity of an MF59\xe2\x84\xa2-adjuvanted subunit influenza vaccine in elderly Chinese subjects" /><meta name="citation_authors" content="Rongcheng Li, Hanhua Fang, Yanping Li, Youping Liu, Michele Pellegrini, Audino Podda" /><meta name="citation_date" content="2008" /><meta name="citation_volume" content="5" /><meta name="citation_firstpage" content="2" /><meta name="citation_doi" content="10.1186/1742-4933-5-2" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2291031/?report=abstract" /><meta name="citation_pmid" content="18289372" /><meta name="DC.Title" content="Safety and immunogenicity of an MF59\xe2\x84\xa2-adjuvanted subunit influenza vaccine in elderly Chinese subjects" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="BioMed Central" /><meta name="DC.Contributor" content="Rongcheng Li" /><meta name="DC.Contributor" content="Hanhua Fang" /><meta name="DC.Contributor" content="Yanping Li" /><meta name="DC.Contributor" content="Youping Liu" /><meta name="DC.Contributor" content="Michele Pellegrini" /><meta name="DC.Contributor" content="Audino Podda" /><meta name="DC.Date" content="2008" /><meta name="DC.Identifier" content="10.1186/1742-4933-5-2" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Safety and immunogenicity of an MF59\xe2\x84\xa2-adjuvanted subunit influenza vaccine in elderly Chinese subjects" /><meta property="og:type" content="article" /><meta property="og:description" content="The safety and immunogenicity of an MF59\xe2\x84\xa2-adjuvanted subunit influenza vaccine (Sub/MF59\xe2\x84\xa2; FLUAD[\xc2\xae] , Novartis Vaccines) was evaluated among elderly Chinese subjects (\xe2\x89\xa5 60 years of age). After a preliminary Phase I, open-label ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291031/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-immage.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2291031/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2291031/pdf/1742-4933-5-2.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1A1C49E99AEEA10000000001EB01EB.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/287/">Immun Ageing</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/162315/">v.5; 2008</a></li><li class="accid">PMC2291031</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-immage.png" alt="Logo of immage" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher\'s site" title="Link to Publisher\'s site" shape="default" coords="0,0,499,74" href="https://immunityageing.biomedcentral.com/" target="pmc_ext" ref="reftype=publisher&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Immun Ageing</span>. 2008; 5: 2. </span></div><div><span class="fm-vol-iss-date">Published online 2008 Feb 20. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2F1742-4933-5-2" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/1742-4933-5-2</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2291031</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/18289372">18289372</a></div></div></div></div><h1 class="content-title">Safety and immunogenicity of an MF59&#x02122;-adjuvanted subunit influenza vaccine in elderly Chinese subjects</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Li%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372" id="A1" class="affpopup" co-rid="_co_idm140554780883728" co-class="co-affbox">Rongcheng Li</a>,<sup>1</sup> <a href="/pubmed/?term=Fang%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372" id="A2" class="affpopup" co-rid="_co_idm140554778131584" co-class="co-affbox">Hanhua Fang</a>,<sup>2</sup> <a href="/pubmed/?term=Li%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372" id="A3" class="affpopup" co-rid="_co_idm140554779476000" co-class="co-affbox">Yanping Li</a>,<sup>1</sup> <a href="/pubmed/?term=Liu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372" id="A4" class="affpopup" co-rid="_co_idm140554771786032" co-class="co-affbox">Youping Liu</a>,<sup>3</sup> <a href="/pubmed/?term=Pellegrini%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372" id="A5" class="affpopup" co-rid="_co_idm140554783655088" co-class="co-affbox">Michele Pellegrini</a>,<sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>4</sup> and  <a href="/pubmed/?term=Podda%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372" id="A6" class="affpopup" co-rid="_co_idm140554849772640" co-class="co-affbox">Audino Podda</a><sup>4</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140554780883728"><h3 class="no_margin">Rongcheng Li</h3><p><sup>1</sup>Centre for Vaccine Clinical Research, Centers for Disease Prevention and Control of Guangxi Zhuang Autonomous Region, 18 Jinzhou Street, 530022 Nanning City, China</p><div>Find articles by <a href="/pubmed/?term=Li%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372">Rongcheng Li</a></div></div><div id="_co_idm140554778131584"><h3 class="no_margin">Hanhua Fang</h3><p><sup>2</sup>National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), Temple of Heaven, Beijing, China</p><div>Find articles by <a href="/pubmed/?term=Fang%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372">Hanhua Fang</a></div></div><div id="_co_idm140554779476000"><h3 class="no_margin">Yanping Li</h3><p><sup>1</sup>Centre for Vaccine Clinical Research, Centers for Disease Prevention and Control of Guangxi Zhuang Autonomous Region, 18 Jinzhou Street, 530022 Nanning City, China</p><div>Find articles by <a href="/pubmed/?term=Li%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372">Yanping Li</a></div></div><div id="_co_idm140554771786032"><h3 class="no_margin">Youping Liu</h3><p><sup>3</sup>Centers for Disease Prevention and Control of Wuzhou, Guangxi Zhuang Autonomous Region, China</p><div>Find articles by <a href="/pubmed/?term=Liu%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372">Youping Liu</a></div></div><div id="_co_idm140554783655088"><h3 class="no_margin">Michele Pellegrini</h3><p><sup>4</sup>Clinical Research Development and Medical Affairs, Novartis Vaccines and Diagnostics, Siena, Italy</p><div>Find articles by <a href="/pubmed/?term=Pellegrini%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372">Michele Pellegrini</a></div></div><div id="_co_idm140554849772640"><h3 class="no_margin">Audino Podda</h3><p><sup>4</sup>Clinical Research Development and Medical Affairs, Novartis Vaccines and Diagnostics, Siena, Italy</p><div>Find articles by <a href="/pubmed/?term=Podda%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18289372">Audino Podda</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140554780229232_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140554780229232_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140554780229232_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140554780229232_ai" style="display:none"><div class="fm-affl" lang="en" id="I1"><sup>1</sup>Centre for Vaccine Clinical Research, Centers for Disease Prevention and Control of Guangxi Zhuang Autonomous Region, 18 Jinzhou Street, 530022 Nanning City, China</div><div class="fm-affl" lang="en" id="I2"><sup>2</sup>National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), Temple of Heaven, Beijing, China</div><div class="fm-affl" lang="en" id="I3"><sup>3</sup>Centers for Disease Prevention and Control of Wuzhou, Guangxi Zhuang Autonomous Region, China</div><div class="fm-affl" lang="en" id="I4"><sup>4</sup>Clinical Research Development and Medical Affairs, Novartis Vaccines and Diagnostics, Siena, Italy</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div><span class="contrib-email" id="A1">Rongcheng Li: <a href="mailto:dev@null" data-email="moc.361@1002hcrl" class="oemail">moc.361@1002hcrl</a>; </span> <span class="contrib-email" id="A2">Hanhua Fang: <a href="mailto:dev@null" data-email="moc.anis@hhfsdj" class="oemail">moc.anis@hhfsdj</a>; </span> <span class="contrib-email" id="A3">Yanping Li: <a href="mailto:dev@null" data-email="moc.621@xzmyxg" class="oemail">moc.621@xzmyxg</a>; </span> <span class="contrib-email" id="A4">Youping Liu: <a href="mailto:dev@null" data-email="moc.361@35.59pyl" class="oemail">moc.361@35.59pyl</a>; </span> <span class="contrib-email" id="A5">Michele Pellegrini: <a href="mailto:dev@null" data-email="moc.sitravon@inirgellep.elehcim" class="oemail">moc.sitravon@inirgellep.elehcim</a>; </span> <span class="contrib-email" id="A6">Audino Podda: <a href="mailto:dev@null" data-email="moc.sitravon@addop.onidua" class="oemail">moc.sitravon@addop.onidua</a></span> </div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140554780229232_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2007 Sep 18; Accepted 2008 Feb 20.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140554780229232_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2008 Li et al; licensee BioMed Central Ltd.</div><div class="license half_rhythm"><p id="__p1">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/2.0" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://creativecommons.org/licenses/by/2.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2291031/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm140554811651792" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140554811651792title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p2" class="p p-first-last">The safety and immunogenicity of an MF59&#x02122;-adjuvanted subunit influenza vaccine (Sub/MF59&#x02122;; FLUAD<sup>&#x000ae;</sup>, Novartis Vaccines) was evaluated among elderly Chinese subjects (&#x02265; 60 years of age). After a preliminary Phase I, open-label study (n = 25) to assess safety 1&#x02013;14 days post-vaccination, a comparative observer-blind, randomised, controlled clinical trial (n = 600) was performed to assess safety and immunogenicity versus a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal<sup>&#x000ae;</sup>, Novartis Vaccines). Subjects were randomised (2:1) to receive Sub/MF59&#x02122; or Subunit.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Results</h3><p id="__p3" class="p p-first-last">Both vaccines were well tolerated, with no vaccine-related serious adverse events reported during the Phase I trial. During the observer-blind study, local and systemic reactions were generally similar for both vaccines 1&#x02013;22 days post-vaccination; however, injection-site induration was more frequent among the Subunit group (P &#x0003c; 0.05), and mild pain at the injection site and fever were more frequent among Sub/MF59&#x02122; recipients (P &#x02264; 0.005). Both vaccines induced a significant (P &#x0003c; 0.001) increase in geometric mean titres (GMTs) for the three strains tested, versus baseline; GMTs against A/H1N1, A/H3N2 and B were significantly higher in the Sub/MF59&#x02122; group (P = 0.034, P &#x0003c; 0.001 and P = 0.005, respectively). GMT ratios against A/H1N1, A/H3N2 and B were also significantly higher in the Sub/MF59&#x02122; group (P = 0.038, P &#x0003c; 0.001 and P = 0.006, respectively). Similarly, the percentage of subjects achieving seroprotection or seroconversion on Day 22 was greater for Sub/MF59&#x02122; recipients, reaching significance for A/H3N2 (P &#x0003c; 0.001).</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Conclusion</h3><p id="__p4" class="p p-first-last">MF59&#x02122;-adjuvanted subunit influenza vaccine is well tolerated by elderly Chinese subjects and induces a higher level of immunogenicity than a non-adjuvanted subunit influenza vaccine in this population that is at high risk of influenza-related complications.</p></div><div id="__sec4" class="sec sec-last"><h3 id="__sec4title">Clinical trial registry</h3><p id="__p5" class="p p-first-last"><a href="http://www.clinicaltrials.gov" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">http://www.clinicaltrials.gov</a>, <a id="__tag_539793124" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00310648" ref="reftype=extlink-clinical-trial&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00310648","term_id":"NCT00310648"}}</span>NCT00310648</a></p></div></div></div><div id="__sec5" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec5title">Background</h2><p id="__p6" class="p p-first">Influenza infection represents a considerable global burden, affecting 5&#x02013;15% of the adult population during annual influenza epidemics [<a href="#B1" rid="B1" class=" bibr popnode">1</a>]. Each year, 3&#x02013;5 million cases of severe illness and 250,000&#x02013;500,000 deaths are thought to result from these epidemics worldwide [<a href="#B1" rid="B1" class=" bibr popnode">1</a>,<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017986">2</a>].</p><p id="__p7">South-east Asia is considered to be the global influenza epicentre, with several pandemic and epidemic strains known to have originated from China and Hong Kong since 1957 [<a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017999">3</a>-<a href="#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_847062807">5</a>]. Furthermore, China is generally acknowledged as an area with a high influenza attack rate, due to the high population density and year-round circulation of the virus in tropical regions [<a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017984">6</a>,<a href="#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017991">7</a>]. In China, pneumonia and influenza combined ranks fourth in the leading causes of death in adults (&#x02265; 40 years of age) [<a href="#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017980">8</a>].</p><p id="__p8">Due to their weakened immune response, the elderly are at increased risk of influenza and its related complications [<a href="#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018004">9</a>]. In China, the annual mortality rate for pneumonia and influenza has been reported to rise to 227.4/100,000 persons in the elderly (&#x02265; 65 years of age), representing a 5-fold increase from the age-standardised annual mortality rate of 43.9/100,000 persons [<a href="#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018012">8</a>]. Furthermore, during 1999, the reported number of influenza-associated deaths in Hong Kong from cardiorespiratory disease, pneumonia and influenza, chronic obstructive pulmonary disease and ischaemic heart disease was higher in the elderly (1697 deaths), compared with adults (205 deaths; 40&#x02013;64 years of age) [<a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017996">10</a>]. Peaks in influenza circulation have been shown to coincide with increased mortality from these conditions, with the elderly accounting for approximately 70&#x02013;90% of the associated deaths [<a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018013">10</a>]. In addition to an increased number of deaths [<a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018006">10</a>,<a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017994">11</a>], the hospitalisation rate for pneumonia and influenza is also high in the elderly [<a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018007">12</a>].</p><p id="__p9">Influenza vaccine effectiveness has been studied extensively, mainly in temperate regions. Conventional influenza vaccines confer protection against laboratory-confirmed influenza in 70&#x02013;90% of young adults (18&#x02013;64 years of age) [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017978">13</a>,<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_312651294">14</a>]; however, these vaccines are less effective (17&#x02013;53%) in the elderly, due in part to the elderly\'s waning immunity [<a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017985">15</a>]. When evaluating vaccine response, however, it is important to also consider racial background. For example, among a racially diverse, healthy elderly population in the USA, a reduced response to influenza vaccine was observed among elderly African Americans, compared with elderly Caucasian and Latinos [<a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018016">16</a>]. Furthermore, racial differences in relation to vaccination have been observed in Taiwan among Han Chinese children compared with Aboriginal children; higher titres against hepatitis B vaccination were reported for Han Chinese children [<a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018000">17</a>].</p><p id="__p10">In Hong Kong, Taiwan and China, vaccination has been shown to offer protection against influenza [<a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018014">18</a>-<a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017981">20</a>]. Influenza vaccination prevented approximately 69% of influenza-related hospitalisation admissions in Hong Kong during the 2003&#x02013;2004 winter season [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017977">19</a>] and was strongly associated with a reduction in pneumonia, heart disease, stroke, diabetes mellitus and renal disease in Taiwan in 2001 [<a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018010">20</a>]. Vaccine effectiveness, however, has also been reported to be lower in elderly Chinese people than in adult Chinese people (68.6% versus 74%, respectively) [<a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017993">18</a>]. Despite the availability of an effective vaccine, coverage rates are low in China; for example, the general vaccination rate among the urban population of Beijing is only 10.5%, falling to 7.9% for those &#x02265; 60 years of age [<a href="#B21" rid="B21" class=" bibr popnode">21</a>]. Thus, because currently available vaccines do not offer optimal protection in the elderly [<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_312651293">14</a>,<a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017979">15</a>] and vaccine coverage rates are low [<a href="#B21" rid="B21" class=" bibr popnode">21</a>], elderly Chinese people are at increased risk of influenza and its related complications. As China has the world\'s largest population of elderly people (&#x0003e;80 million) [<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018015">22</a>], influenza represents a considerable health and economic burden.</p><p id="__p11">To meet the global challenge presented by waning immunity in the elderly, vaccines that offer the elderly enhanced immunogenicity and increased clinical protection are required. Addition of the adjuvant MF59&#x02122; [<a href="#B23" rid="B23" class=" bibr popnode">23</a>] to subunit influenza vaccine (MF59&#x02122;-adjuvanted subunit influenza vaccine; FLUAD<sup>&#x000ae;</sup>, Novartis Vaccines) has been shown to enhance the immune response and offer increased clinical protection in elderly subjects, compared with non-adjuvanted subunit influenza vaccine [<a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017995">24</a>-<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018002">26</a>]. Furthermore, enhanced immunogenicity is observed in elderly subjects with underlying chronic conditions, who are at especially high risk of influenza and its complications [<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018011">27</a>]. Vaccination of elderly subjects with the MF59&#x02122;-adjuvanted subunit influenza vaccine also confers protection against a broader range of influenza virus strains than non-adjuvanted subunit influenza vaccine [<a href="#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018005">28</a>,<a href="#B29" rid="B29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017990">29</a>] and has been associated with a reduced risk of hospitalisation for pneumonia and cerebrovascular disease in non-institutionalised elderly subjects [<a href="#B30" rid="B30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018009">30</a>,<a href="#B31" rid="B31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017976">31</a>].</p><p id="__p12" class="p p-last">In China, the registration of FLUAD<sup>&#x000ae; </sup>for use in elderly people is currently under consideration. For this reason, a randomised comparative trial was performed in a large cohort of elderly Chinese people to assess the safety and immunogenicity of FLUAD<sup>&#x000ae; </sup>against a non-adjuvanted subunit influenza vaccine.</p></div><div id="__sec6" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec6title">Results</h2><p id="__p13" class="p p-first">All subjects (n = 25) enrolled in the Phase I open-label trial completed the safety evaluation. One subject was excluded from the analysis due to administration of Subunit vaccine, rather than Sub/MF59&#x02122;. For the Phase II/III trial, the baseline characteristics of the study population were similar for the Sub/MF59&#x02122; and Subunit vaccine groups, with an equal match for gender, age and availability of current and past medical history. A total of 600 subjects were recruited in the subsequent Phase II/III trial and randomised to receive Sub/MF59&#x02122; (n = 400) or Subunit (n = 200) vaccine. Safety evaluation was completed for 589 subjects and serological analysis was performed for 554 subjects (Figure <a href="/pmc/articles/PMC2291031/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1).</span></span><span>1</span></a>). The major reasons for patient withdrawal were refusal to continue the study (25 and 10 subjects receiving Sub/MF59&#x02122; and Subunit, respectively), a change in residence or hospital/being unable to receive follow-up as too busy (4 patients, 2 in each vaccine group) or other drop-out (6 and 1 subjects receiving Sub/MF59&#x02122; and Subunit, respectively). No subjects were withdrawn from the study because of an AE due to the study vaccines.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2291031/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554775054240" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2291031_1742-4933-5-2-1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 1742-4933-5-2-1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2291031/bin/1742-4933-5-2-1.jpg" /></a></div><div id="largeobj_idm140554775054240" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2291031/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p14">Subject participation in the Phase II/III trial.</p></div></div></div><div id="__sec7" class="sec"><h3 id="__sec7title">Safety</h3><p id="__p15" class="p p-first">Both vaccines were well tolerated by elderly subjects during the clinical trials. No vaccine-related serious adverse events (SAEs) were reported for Sub/MF59&#x02122; during the Phase I trial, which was a pre-requisite for continuation with the Phase II/III trial.</p><p id="__p16" class="p">In the Phase II/III trial, the overall incidence of systemic reactions and AEs was generally similar between the Sub/MF59&#x02122; and Subunit groups; however, the incidence of local reactions was significantly (P = 0.012) higher in the Sub/MF59&#x02122; group compared with the Subunit group (24.0% versus 15.2%, respectively) (Table <a href="/pmc/articles/PMC2291031/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). Induration at the injection site was significantly (P &#x0003c; 0.05) more frequent in the Subunit group compared with the Sub/MF59&#x02122; group (2.5% versus 0.5%, respectively) (Table <a href="/pmc/articles/PMC2291031/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table2).</span></span><span>2</span></a>). Pain at the injection site and fever (axillary temperature &#x0003e;38&#x000b0;C) were significantly (P &#x02264; 0.005) more frequent in the Sub/MF59&#x02122; group compared with the Subunit group (10.2% versus 3.0% and 15.9% versus 7.6%, respectively) (Table <a href="/pmc/articles/PMC2291031/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table2).</span></span><span>2</span></a>). Local and systemic reactions were generally mild or moderate and transient. In particular, fever was mainly classed as mild or moderate in the Sub/MF59&#x02122; and Subunit groups and pain was classified as mild. No vaccine-related SAEs were reported during this large study for the Subunit group; however, a vaccine-related SAE (high fever) was reported for one subject (0.3%) in the Sub/MF59&#x02122; group (Table <a href="/pmc/articles/PMC2291031/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1</span></span><span>1</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p17">Incidence of adverse events (AEs), adverse reactions and serious AEs (SAEs) for the two vaccine groups</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554778208656" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1"></td><td align="center" colspan="2" rowspan="1"><strong>Incidence, %(n)</strong></td><td align="center" rowspan="1" colspan="1"><strong>P-value</strong></td></tr><tr><td rowspan="1" colspan="1"></td><td colspan="2" rowspan="1"><hr /></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><strong>Sub/MF59&#x02122; (n = 391)</strong></td><td align="center" rowspan="1" colspan="1"><strong>Subunit (n = 198)</strong></td><td rowspan="1" colspan="1"></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><strong>Local reactions</strong></td><td align="center" rowspan="1" colspan="1">24.0(94)</td><td align="center" rowspan="1" colspan="1">15.2(30)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>Systemic reactions</strong></td><td align="center" rowspan="1" colspan="1">10.7(42)</td><td align="center" rowspan="1" colspan="1">9.6(19)</td><td align="center" rowspan="1" colspan="1">0.666</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>AEs</strong></td><td align="center" rowspan="1" colspan="1">6.1(24)</td><td align="center" rowspan="1" colspan="1">6.6(13)</td><td align="center" rowspan="1" colspan="1">0.840</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>SAEs</strong></td><td align="center" rowspan="1" colspan="1">1.0(4)</td><td align="center" rowspan="1" colspan="1">0.5(1)</td><td align="center" rowspan="1" colspan="1">0.668</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>Vaccine-related AEs (definitely, probably or possibly related to the vaccine)</strong></td><td align="center" rowspan="1" colspan="1">3.8(15)</td><td align="center" rowspan="1" colspan="1">5.1(10)</td><td align="center" rowspan="1" colspan="1">0.490</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>Vaccine-related SAEs (definitely, probably or possibly related to the vaccine)</strong></td><td align="center" rowspan="1" colspan="1">0.3(1)</td><td align="center" rowspan="1" colspan="1">0.0(0)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr></tbody></table></div><div id="largeobj_idm140554778208656" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p18">Sub/MF59&#x02122;, MF59&#x02122;-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine</p></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p19">Incidence of local and systemic reactions reported for the two vaccine groups</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554853702528" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><strong>Sub/MF59&#x02122; %(n)</strong></td><td align="center" rowspan="1" colspan="1"><strong>Subunit %(n)</strong></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Local reaction</td><td align="right" rowspan="1" colspan="1"><em>Rash</em></td><td align="center" rowspan="1" colspan="1">0.0(0)</td><td align="center" rowspan="1" colspan="1">0.5(1)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Erythema</em></td><td align="center" rowspan="1" colspan="1">1.5(6)</td><td align="center" rowspan="1" colspan="1">1.5(3)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Induration</em></td><td align="center" rowspan="1" colspan="1">0.5(2)</td><td align="center" rowspan="1" colspan="1">2.5(5)*</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Swelling</em></td><td align="center" rowspan="1" colspan="1">2.8(11)</td><td align="center" rowspan="1" colspan="1">1.0(2)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Pain</em></td><td align="center" rowspan="1" colspan="1">10.2(40)**</td><td align="center" rowspan="1" colspan="1">3.0(6)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Pruritus</em></td><td align="center" rowspan="1" colspan="1">1.3(5)</td><td align="center" rowspan="1" colspan="1">3.0(6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic reaction</td><td align="right" rowspan="1" colspan="1"><em>Headache</em></td><td align="center" rowspan="1" colspan="1">3.6(14)</td><td align="center" rowspan="1" colspan="1">2.5(5)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Fever</em></td><td align="center" rowspan="1" colspan="1">15.9(62)**</td><td align="center" rowspan="1" colspan="1">7.6(15)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Tiredness</em></td><td align="center" rowspan="1" colspan="1">3.3(13)</td><td align="center" rowspan="1" colspan="1">1.0(2)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Diarrhoea</em></td><td align="center" rowspan="1" colspan="1">0.8(3)</td><td align="center" rowspan="1" colspan="1">2.0(4)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Vomiting</em></td><td align="center" rowspan="1" colspan="1">1.0(4)</td><td align="center" rowspan="1" colspan="1">1.0(2)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Myalgia</em></td><td align="center" rowspan="1" colspan="1">1.8(7)</td><td align="center" rowspan="1" colspan="1">0.5(1)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Cough</em></td><td align="center" rowspan="1" colspan="1">2.0(8)</td><td align="center" rowspan="1" colspan="1">2.0(4)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Angina</em></td><td align="center" rowspan="1" colspan="1">1.5(6)</td><td align="center" rowspan="1" colspan="1">1.0(2)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Watery nasal discharge</em></td><td align="center" rowspan="1" colspan="1">1.0(4)</td><td align="center" rowspan="1" colspan="1">1.0(2)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Skin disease (e.g. eczema)</em></td><td align="center" rowspan="1" colspan="1">0.0(0)</td><td align="center" rowspan="1" colspan="1">1.0(2)</td></tr><tr><td rowspan="1" colspan="1"></td><td align="right" rowspan="1" colspan="1"><em>Irritability</em></td><td align="center" rowspan="1" colspan="1">0.0(0)</td><td align="center" rowspan="1" colspan="1">0.5(1)</td></tr></tbody></table></div><div id="largeobj_idm140554853702528" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p20">*P &#x0003c; 0.05 versus the Sub/MF59&#x02122; vaccine group; **P &#x02264; 0.005 versus the Subunit vaccine group</p><p id="__p21">Sub/MF59&#x02122;, MF59&#x02122;-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine</p></div></div></div><div id="__sec8" class="sec sec-last"><h3 id="__sec8title">Immunogenicity</h3><p id="__p22" class="p p-first">Pre-vaccination GMTs were similar for both vaccine groups against all three influenza strains tested. Baseline seroprotection rates were also similar between vaccine groups, with &#x0003e;97% of subjects in each vaccine cohort seroprotected against A/H1N1 (Sub/MF59&#x02122;, 98.4%; Subunit, 97.3%), &#x0003e;18% against A/H3N2 (Sub/MF59&#x02122;, 21.5%; Subunit, 18.7%) and &#x0003e;2% against B (Sub/MF59&#x02122;, 2.2%; Subunit, 2.1%) prior to vaccination (Table <a href="/pmc/articles/PMC2291031/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table3</span></span><span>3</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p23">Pre- and post-vaccination seroprotection rate (percentage of subjects with haemagglutination inhibition titre &#x02265; 1:40)</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554812673008" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1"><strong>Viral strain</strong></td><td align="left" rowspan="1" colspan="1"><strong>Vaccination status</strong></td><td align="center" rowspan="1" colspan="1"><strong>Sub/MF59&#x02122;, % (n = 367)</strong></td><td align="center" rowspan="1" colspan="1"><strong>Subunit, % (n = 187)</strong></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><strong>A/H1N1</strong></td><td align="left" rowspan="1" colspan="1">Pre-vaccination</td><td align="center" rowspan="1" colspan="1">98.4</td><td align="center" rowspan="1" colspan="1">97.3</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Post-vaccination</td><td align="center" rowspan="1" colspan="1">99.7</td><td align="center" rowspan="1" colspan="1">99.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>A/H3N2</strong></td><td align="left" rowspan="1" colspan="1">Pre-vaccination</td><td align="center" rowspan="1" colspan="1">21.5</td><td align="center" rowspan="1" colspan="1">18.7</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Post-vaccination</td><td align="center" rowspan="1" colspan="1">88.0*</td><td align="center" rowspan="1" colspan="1">72.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>B</strong></td><td align="left" rowspan="1" colspan="1">Pre-vaccination</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">2.1</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Post-vaccination</td><td align="center" rowspan="1" colspan="1">35.7</td><td align="center" rowspan="1" colspan="1">28.3</td></tr></tbody></table></div><div id="largeobj_idm140554812673008" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p24">*P &#x0003c; 0.001 versus the Subunit group</p><p id="__p25">Sub/MF59&#x02122;, MF59&#x02122;-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine</p></div></div><p id="__p26">At 3 weeks post-vaccination, significantly (P &#x0003c; 0.001) higher GMTs were reported for both vaccine groups versus baseline (data not shown); however, in the Sub/MF59&#x02122; group, post-vaccination GMTs against all three strains were significantly higher compared with the Subunit group (A/H1N1, 1439.01 versus 1197.39, respectively, P = 0.034; A/H3N2, 274.61 versus 110.85, respectively, P &#x0003c; 0.001; B, 16.59 versus 11.95, respectively, P = 0.005). Furthermore, GMT ratios (Day 22:Day 1) against the A/H1N1, A/H3N2 and B strains were significantly (P = 0.038, P &#x0003c; 0.001, P = 0.006, respectively) greater in the Sub/MF59&#x02122; group compared with the Subunit group (Figure <a href="/pmc/articles/PMC2291031/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2).</span></span><span>2</span></a>). Following analysis of the data, including only those subjects who did not have seroprotective titres prior to vaccination, the same trend was found: higher post-vaccination GMTs were reported in the Sub/MF59&#x02122; group compared with the Subunit group for the A/H3N2 and B strains (P &#x0003c; 0.001 and P = 0.008, respectively), but not for A/H1N1 (Figure <a href="/pmc/articles/PMC2291031/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3</span></span><span>3</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC2291031/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554778368768" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2291031_1742-4933-5-2-2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 1742-4933-5-2-2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2291031/bin/1742-4933-5-2-2.jpg" /></a></div><div id="largeobj_idm140554778368768" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC2291031/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p27">Geometric mean titre ratios (Day22:Day1) in all subjects in the Phase II/III trial.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC2291031/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554813170128" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2291031_1742-4933-5-2-3.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 1742-4933-5-2-3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2291031/bin/1742-4933-5-2-3.jpg" /></a></div><div id="largeobj_idm140554813170128" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC2291031/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p28">Pre-vaccination (Day 1) and post-vaccination (Day 22) geometric mean titre against a) A/H1N1, b) A/H3N2 and c) B viral strains in subjects without pre-vaccination immunoprotection.</p></div></div></div><p id="__p29" class="p">Post-vaccination, the percentage of subjects seroprotected against the A/H3N2 strain was significantly (P &#x0003c; 0.001) greater after vaccination with Sub/MF59&#x02122; compared with Subunit vaccination (Table <a href="/pmc/articles/PMC2291031/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table3).</span></span><span>3</span></a>). Although the seroprotection rate for all subjects against the A/H1N1 and B strains was higher in the Sub/MF59&#x02122; group, no significant difference was found between vaccine groups. In addition, a significantly (P &#x0003c; 0.001) greater number of previously unprotected elderly subjects in the Sub/MF59&#x02122; vaccine group demonstrated seroconversion against the A/H3N2 strain, compared with the Subunit group (85.1 versus 66.2%, respectively) (Table <a href="/pmc/articles/PMC2291031/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table4</span></span><span>4</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T4"><h3>Table 4</h3><!--caption a7--><div class="caption"><p id="__p30">Seroconversion rates (percentage of subjects with seroconversion<sup>a </sup>or a significant increase in HI titres<sup>b </sup>in subjects without pre-vaccination immunoprotection)</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140554774824960" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td rowspan="1" colspan="1"></td><td align="center" colspan="2" rowspan="1"><strong>Seroconversion rates, %</strong></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><strong>Viral strain</strong></td><td align="center" rowspan="1" colspan="1"><strong>Sub/MF59&#x02122;</strong></td><td align="center" rowspan="1" colspan="1"><strong>Subunit</strong></td></tr><tr><td colspan="3" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>A/H1N1<sup>c</sup></strong></td><td align="center" rowspan="1" colspan="1">83.3</td><td align="center" rowspan="1" colspan="1">80.0</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>A/H3N2<sup>d</sup></strong></td><td align="center" rowspan="1" colspan="1">85.1*</td><td align="center" rowspan="1" colspan="1">66.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>B<sup>e</sup></strong></td><td align="center" rowspan="1" colspan="1">33.4</td><td align="center" rowspan="1" colspan="1">25.8</td></tr></tbody></table></div><div id="largeobj_idm140554774824960" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2291031/table/T4/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p31"><sup>a</sup>Seroconversion is defined as negative pre-vaccination serum (i.e. haemagglutinin inhibition [HI] titre &#x0003c;1:10) and post-vaccination HI titre &#x02265; 1:40; <sup>b</sup>Significant increase is defined as &#x02265; 4-fold increase from non-negative (&#x02265; 1:10) pre-vaccination HI titre; <sup>c</sup>Number of subjects: Sub/MF59&#x02122;, 6; Subunit, 5; <sup>d</sup>Number of subjects: Sub/MF59&#x02122;, 288; Subunit, 152; <sup>e</sup>Number of subjects: Sub/MF59&#x02122;, 359; Subunit, 183</p><p id="__p32">*P &#x0003c; 0.001 versus the Subunit group</p><p id="__p33">Sub/MF59&#x02122;, MF59&#x02122;-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine</p></div></div></div></div><div id="__sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec9title">Discussion</h2><p id="__p34" class="p p-first">This study has demonstrated that MF59&#x02122;-adjuvanted subunit influenza vaccine is as well tolerated as non-adjuvanted subunit influenza vaccine in elderly Chinese subjects. Although the number and incidence of some of the solicited local reactions in the Sub/MF59&#x02122; vaccine group was greater than in the Subunit group, they were generally mild or moderate and of short duration, and no subjects withdrew from the study due to safety concerns. Furthermore, the incidence of injection-site pain reported here was lower than has been reported in other studies [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017989">25</a>,<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017997">27</a>]. Although the incidence of fever was higher than has been reported previously with MF59&#x02122;-adjuvanted influenza vaccination [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017975">25</a>,<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018017">27</a>], the increased incidence was evident for both vaccines used in this study, rather than for the Sub/MF59&#x02122; vaccine only. The increase does not appear to be due to race, as in a previous study in elderly Chinese subjects [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018003">19</a>] the incidence of fever was 0% following vaccination with non-adjuvanted influenza vaccine. These findings are in agreement with the published results of clinical trials conducted in elderly Caucasian populations in Europe [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017983">25</a>]. These trials supported registration of the vaccine in Europe, and concluded that the addition of MF59&#x02122; to subunit influenza vaccines does not cause clinically important changes in the safety profile of the influenza vaccine. To date, more than 30 million doses of the MF59&#x02122;-adjuvanted subunit influenza vaccine have been sold, and it has demonstrated a good safety profile [<a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017992">32</a>]. Evaluation of post-marketing pharmacovigilance case reports (n = 385; September 1997 to April 2006) confirmed that vaccination with the MF59&#x02122;-adjuvanted subunit influenza vaccine was associated with a very low frequency of adverse reactions [<a href="#B33" rid="B33" class=" bibr popnode">33</a>].</p><p id="__p35">Evaluation of the primary (pre- and post-vaccination GMTs and GMT ratio) and secondary (proportion of subjects with protective antibody titres [&#x02265; 40] and those demonstrating seroconversion post-vaccination) immunogenicity parameters showed that both the Sub/MF59&#x02122; and Subunit vaccines were able to induce an immune response in elderly Chinese subjects. Significantly (P &#x0003c; 0.05) higher antibody titres were induced by the Sub/MF59&#x02122; vaccine compared with the Subunit vaccine. Furthermore, as for the safety profile, the immunogenicity results agree with the results of trials conducted in Europe [<a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017982">24</a>,<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018018">25</a>,<a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018008">27</a>]. For all three influenza strains tested, both the MF59&#x02122;-adjuvanted and the non-adjuvanted vaccine met at least one criterion of the European Committee for Medicinal Products for Human Use (CHMP) criteria for the immunogenicity evaluation of seasonal influenza vaccines, as required for vaccine licensure [<a href="#B34" rid="B34" class=" bibr popnode">34</a>]. For both vaccines, the trend was for higher immunogenicity for the influenza A strains, compared to the B strain. It is of note that very high pre-vaccination titres were recorded in this study, especially for A/H1N1. This could be explained in part by the A/H1N1 vaccine strain (A/New Caledonia/20/99-like H1N1) being included in the vaccine formulation for several influenza seasons previous to the 2005&#x02013;2006 season. Furthermore, from an epidemiological standpoint, influenza A strains are often the most dominant and the most relevant strains among adults and the elderly, with A/H1N1 having been the predominant circulating strain in the Guangxi region of China during the time before the trial was conducted.</p><p id="__p36">It is well documented that levels of HI antibody titres correlate with seroprotection against influenza [<a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017987">35</a>], thus it is expected that increased immunogenicity should lead to increased clinical protection from influenza. This approach has been widely used across the clinical trial programme for the MF59&#x02122;-adjuvanted vaccine [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148018001">25</a>]. During field studies in Europe, MF59&#x02122;-adjuvanted vaccine has been shown to offer greater clinical protection against influenza-like illness compared with non-adjuvanted vaccine [<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_148017988">26</a>]. Therefore, it is anticipated that MF59&#x02122;-adjuvanted vaccine may also offer greater clinical protection in elderly Chinese subjects.</p><p id="__p37" class="p p-last">Results from trials using an MF59&#x02122;-adjuvanted subunit influenza vaccine suggest that adjuvanted vaccination induces a greater immune response in elderly (&#x02265; 60 years of age) Chinese subjects, and demonstrates a good tolerability profile, compared with a non-adjuvanted subunit influenza vaccine.</p></div><div id="__sec10" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec10title">Conclusion</h2><p id="__p38" class="p p-first-last">In conclusion, the study results strengthen support for the use of the MF59&#x02122;-adjuvanted subunit influenza vaccine (FLUAD<sup>&#x000ae;</sup>) among the elderly population in China.</p></div><div id="__sec11" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec11title">Methods</h2><div id="__sec12" class="sec sec-first"><h3 id="__sec12title">Study design</h3><p id="__p39" class="p p-first">A preliminary Phase I, open-label study was conducted in February-March 2006 to assess the safety of an MF59&#x02122;-adjuvanted subunit influenza vaccine (Sub/MF59&#x02122;; FLUAD&#x000ae;, Novartis Vaccines) in elderly Chinese subjects. The study recruited 25 Chinese subjects (&#x02265; 60 years of age); of these, 24 subjects were administered Sub/MF59&#x02122; in follow-up sequence.</p><p id="__p40" class="p p-last">Following this safety trial, a Phase II/III randomised, observer-blind, controlled study was conducted to assess the safety and immunogenicity of Sub/MF59&#x02122; in a large cohort of elderly (&#x02265; 60 years of age) Chinese subjects. Subjects were randomised (2:1) to receive either Sub/MF59&#x02122; (n = 400) or a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal&#x000ae;, Novartis Vaccines; n = 200). Both vaccines included the strains recommended for the 2005&#x02013;2006 Northern hemisphere influenza season. Randomisation was achieved using the PEMS V2.1 statistical software (Statistics Teaching and Research Division, West China University of Medical Sciences; released January 1996). A 0.5 ml dose was administered intramuscularly in the deltoid region of the non-dominant arm.</p></div><div id="__sec13" class="sec"><h3 id="__sec13title">Study population</h3><div id="__sec14" class="sec sec-first"><h4 id="__sec14title">Inclusion criteria</h4><p id="__p41" class="p p-first-last">Subjects invited to participate in the trial were those &#x02265; 60 years of age, who were healthy and willing/able to provide written informed consent prior to study entry.</p></div><div id="__sec15" class="sec sec-last"><h4 id="__sec15title">Exclusion criteria</h4><p id="__p42" class="p p-first">Subjects with underlying disease chronic, such as tumours, autoimmune diseases, progressive artherosclerosis or complicated diabetes mellitus, chronic obstructive pulmonary disorder requiring oxygen therapy, acute or progressive liver or renal disease, or congestive heart failure; subjects with a known allergy to any vaccine components; subjects with laboratory-confirmed influenza or vaccinated against influenza within 6 months prior to enrolment; subjects who had received any other vaccine or investigational agent within 4 weeks prior to enrolment; subjects with current infectious disease, including those taking systemic antibiotics or antivirals.</p><p id="__p43" class="p p-last">Both the pivotal safety study and the subsequent trial were performed according to the ethical guidelines of the 1975 Declaration of Helsinki, Good Clinical Practice, and local laws. Before the trials started, the study protocol and informed consent form were approved by local ethics committees; all subjects signed an Informed Consent Form.</p></div></div><div id="__sec16" class="sec"><h3 id="__sec16title">Objectives</h3><div id="__sec17" class="sec sec-first"><h4 id="__sec17title">Safety</h4><p id="__p44" class="p p-first-last">Local and systemic reactions, including all adverse events (AEs), were monitored and recorded 14 days post-vaccination for the Phase I trial and 22 days post-vaccination for the Phase II/III trial, controlled study.</p></div><div id="__sec18" class="sec sec-last"><h4 id="__sec18title">Immunogenicity</h4><p id="__p45" class="p p-first-last">For the Phase II/III trial, blood samples were taken from all subjects pre-vaccination (Day 1) and post-vaccination (Day 22). Haemagglutinin inhibition (HI) antibody titres were measured in all samples. <em>Primary parameters</em>: Geometric mean titres (GMTs) against A/New Caledonia/20/99-like (A/H1N1), A/California/7/2004-like (A/H3N2) and B/Shanghai/361/2002-like influenza strains were measured for each vaccine pre- and post-vaccination (Day 1 and Day 22). The geometric mean titre ratio (GMR) of post-vaccination titres versus pre-vaccination titres was also reported. <em>Secondary parameters</em>: For each influenza strain, the number of subjects with seroprotective HI antibody titres (&#x02265; 1:40) was also evaluated pre-vaccination and post-vaccination (Day 1 and Day 22), and the number of subjects achieving seroconversion (defined as &#x02265; 4-fold increase in HI titre from non-negative pre-vaccination titre [&#x02265; 1:10] or a rise from &#x0003c;1:10 to a post-vaccination HI titre &#x02265; 1:40) post-vaccination (Day 22) was calculated.</p></div></div><div id="__sec19" class="sec sec-last"><h3 id="__sec19title">Statistical methods, analysis and objectives</h3><p id="__p46" class="p p-first-last">Data were analysed using the SAS V8.2 software. Statistical significance between vaccine groups for data describing the population\'s baseline characteristics was calculated using the Student\'s t-test and the chi-square test, or Fisher\'s exact test where necessary. Analysis of covariance was performed to calculate the confidence intervals for GMTs at Day 22, with GMT at Day 1 as covariate. Paired t-tests were performed to assess the difference between pre- and post-vaccination GMTs within each vaccine group. A P-value of &#x0003c;0.05 was considered to indicate statistical significance.</p></div></div><div id="__sec20" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec20title">Competing interests</h2><p id="__p47" class="p p-first-last">The study was funded by Novartis Vaccines, and Michele Pellegrini and Audino Podda are employees of Novartis Vaccines. The remaining authors declare that they have no competing interests.</p></div><div id="__sec21" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec21title">Authors\' contributions</h2><p id="__p48" class="p p-first-last">RL and HF were responsible for the design, co-ordination and conduct of the clinical trial and the statistical analysis. RL, HF, YL, YL, MP and AP consulted the clinical results and prepared the manuscript. All authors read and approved the final manuscript.</p></div><div id="idm140554849493392" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140554849493392title">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:decimal;"><li id="B1"><span class="citation">World Health Organization  WHO factsheet 211: Influenza. 2003. <a href="http://who.int/mediacentre/factsheets/2003/fs211/en/print.html" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://who.int/mediacentre/factsheets/2003/fs211/en/print.html</a> Accessed February 2007.</span></li><li id="B2"><span class="citation">World Health Organization  Influenza vaccines: WHO position paper. <span><span class="ref-journal">Wkly Epidemiol Rec. </span>2005;<span class="ref-vol">80</span>:279\xe2\x80\x93287.</span> [<a href="/pubmed/16171031" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Wkly+Epidemiol+Rec&amp;title=Influenza+vaccines:+WHO+position+paper&amp;volume=80&amp;publication_year=2005&amp;pages=279-287&amp;pmid=16171031&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B3"><span class="citation">Webster RG. Predictions for future human influenza pandemics. <span><span class="ref-journal">J Infect Dis. </span>1997;<span class="ref-vol">176</span>:S14\xe2\x80\x9319. doi: 10.1086/514168.</span> [<a href="/pubmed/9240688" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F514168" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Predictions+for+future+human+influenza+pandemics&amp;author=RG+Webster&amp;volume=176&amp;publication_year=1997&amp;pages=S14-19&amp;pmid=9240688&amp;doi=10.1086/514168&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B4"><span class="citation">Huang P, Ni H, Shen G, Zhou H, Peng G, Liu S. Analysis of the 1991&#x02013;2000 influenza epidemic in Guangdong Province, China. <span><span class="ref-journal">Southeast Asian J Trop Med Public Health. </span>2001;<span class="ref-vol">32</span>:787\xe2\x80\x93790.</span> [<a href="/pubmed/12041555" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Southeast+Asian+J+Trop+Med+Public+Health&amp;title=Analysis+of+the+1991&#x02013;2000+influenza+epidemic+in+Guangdong+Province,+China&amp;author=P+Huang&amp;author=H+Ni&amp;author=G+Shen&amp;author=H+Zhou&amp;author=G+Peng&amp;volume=32&amp;publication_year=2001&amp;pages=787-790&amp;pmid=12041555&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B5"><span class="citation">Nicholson KG, Wood JM, Zambon M. Influenza. <span><span class="ref-journal">Lancet. </span>2003;<span class="ref-vol">362</span>:1733\xe2\x80\x931745. doi: 10.1016/S0140-6736(03)14854-4.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7112395/">PMC free article</a>]</span> [<a href="/pubmed/14643124" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0140-6736(03)14854-4" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Influenza&amp;author=KG+Nicholson&amp;author=JM+Wood&amp;author=M+Zambon&amp;volume=362&amp;publication_year=2003&amp;pages=1733-1745&amp;pmid=14643124&amp;doi=10.1016/S0140-6736(03)14854-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B6"><span class="citation">Shortridge KF. Severe acute respiratory syndrome and influenza: virus incursions from southern China. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2003;<span class="ref-vol">168</span>:1416\xe2\x80\x931420. doi: 10.1164/rccm.2310005.</span> [<a href="/pubmed/14668255" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1164%2Frccm.2310005" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Respir+Crit+Care+Med&amp;title=Severe+acute+respiratory+syndrome+and+influenza:+virus+incursions+from+southern+China&amp;author=KF+Shortridge&amp;volume=168&amp;publication_year=2003&amp;pages=1416-1420&amp;pmid=14668255&amp;doi=10.1164/rccm.2310005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B7"><span class="citation">Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. <span><span class="ref-journal">PLoS Med. </span>2006;<span class="ref-vol">3</span>:e89. doi: 10.1371/journal.pmed.0030089.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1391975/">PMC free article</a>]</span> [<a href="/pubmed/16509764" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1371%2Fjournal.pmed.0030089" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Med&amp;title=Influenza+in+tropical+regions&amp;author=C+Viboud&amp;author=WJ+Alonso&amp;author=L+Simonsen&amp;volume=3&amp;publication_year=2006&amp;pages=e89&amp;pmid=16509764&amp;doi=10.1371/journal.pmed.0030089&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B8"><span class="citation">He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen C-S, Chen J, Wildman RP, Klag MJ, Whelton PK. Major causes of death among men and women in China. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">353</span>:1124\xe2\x80\x931134. doi: 10.1056/NEJMsa050467.</span> [<a href="/pubmed/16162883" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMsa050467" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Major+causes+of+death+among+men+and+women+in+China&amp;author=J+He&amp;author=D+Gu&amp;author=X+Wu&amp;author=K+Reynolds&amp;author=X+Duan&amp;volume=353&amp;publication_year=2005&amp;pages=1124-1134&amp;pmid=16162883&amp;doi=10.1056/NEJMsa050467&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B9"><span class="citation">Targonski PV, Jacobson RM, Poland GA. Immunosenescence: Role and measurement in influenza vaccine response among the elderly. <span><span class="ref-journal">Vaccine. </span>2007;<span class="ref-vol">25</span>:3066\xe2\x80\x933069. doi: 10.1016/j.vaccine.2007.01.025.</span> [<a href="/pubmed/17275144" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2007.01.025" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Immunosenescence:+Role+and+measurement+in+influenza+vaccine+response+among+the+elderly&amp;author=PV+Targonski&amp;author=RM+Jacobson&amp;author=GA+Poland&amp;volume=25&amp;publication_year=2007&amp;pages=3066-3069&amp;pmid=17275144&amp;doi=10.1016/j.vaccine.2007.01.025&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B10"><span class="citation">Wong CM, Chan KP, Hedley AJ, Peiris JS. Influenza-associated mortality in Hong Kong. <span><span class="ref-journal">Clin Infect Dis. </span>2004;<span class="ref-vol">39</span>:1611\xe2\x80\x931617. doi: 10.1086/425315.</span> [<a href="/pubmed/15578360" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F425315" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Infect+Dis&amp;title=Influenza-associated+mortality+in+Hong+Kong&amp;author=CM+Wong&amp;author=KP+Chan&amp;author=AJ+Hedley&amp;author=JS+Peiris&amp;volume=39&amp;publication_year=2004&amp;pages=1611-1617&amp;pmid=15578360&amp;doi=10.1086/425315&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B11"><span class="citation">Hsieh YC, Chen HY, Yen JJ, Liu PD, Chang LY, Lu CY, Shao PL, Lee CY, Huang LM. Influenza in Taiwan: seasonality and vaccine strain match. <span><span class="ref-journal">J Microbiol Immunol Infect. </span>2005;<span class="ref-vol">38</span>:238\xe2\x80\x93243.</span> [<a href="/pubmed/16118670" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Microbiol+Immunol+Infect&amp;title=Influenza+in+Taiwan:+seasonality+and+vaccine+strain+match&amp;author=YC+Hsieh&amp;author=HY+Chen&amp;author=JJ+Yen&amp;author=PD+Liu&amp;author=LY+Chang&amp;volume=38&amp;publication_year=2005&amp;pages=238-243&amp;pmid=16118670&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B12"><span class="citation">Wong CM, Yang L, Chan KP, Leung G, Chan KH, Guan Y, Lam TH, Hedley AJ, Peiris JSM. Influenza-associated hospitalization in a subtropical city. <span><span class="ref-journal">PLoS Med. </span>2006;<span class="ref-vol">3</span>:e121. doi: 10.1371/journal.pmed.0030121.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1391978/">PMC free article</a>]</span> [<a href="/pubmed/16515368" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1371%2Fjournal.pmed.0030121" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Med&amp;title=Influenza-associated+hospitalization+in+a+subtropical+city&amp;author=CM+Wong&amp;author=L+Yang&amp;author=KP+Chan&amp;author=G+Leung&amp;author=KH+Chan&amp;volume=3&amp;publication_year=2006&amp;pages=e121&amp;pmid=16515368&amp;doi=10.1371/journal.pmed.0030121&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B13"><span class="citation">Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. <span><span class="ref-journal">Vaccine. </span>2003;<span class="ref-vol">21</span>:1769\xe2\x80\x931775. doi: 10.1016/S0264-410X(03)00070-7.</span> [<a href="/pubmed/12686092" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0264-410X(03)00070-7" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=The+efficacy,+effectiveness+and+cost-effectiveness+of+inactivated+influenza+virus+vaccines&amp;author=KL+Nichol&amp;volume=21&amp;publication_year=2003&amp;pages=1769-1775&amp;pmid=12686092&amp;doi=10.1016/S0264-410X(03)00070-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B14"><span class="citation">Centers for Disease Control and Prevention (CDC)  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. <span><span class="ref-journal">MMWR Recomm Rep. </span>2007;<span class="ref-vol">56</span>:1\xe2\x80\x9354.</span> [<a href="/pubmed/17625497" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=MMWR+Recomm+Rep&amp;title=Prevention+and+control+of+influenza.+Recommendations+of+the+Advisory+Committee+on+Immunization+Practices+(ACIP),+2007&amp;volume=56&amp;publication_year=2007&amp;pages=1-54&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B15"><span class="citation">Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. <span><span class="ref-journal">Vaccine. </span>2006;<span class="ref-vol">24</span>:1159\xe2\x80\x931169. doi: 10.1016/j.vaccine.2005.08.105.</span> [<a href="/pubmed/16213065" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2005.08.105" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Antibody+response+to+influenza+vaccination+in+the+elderly:+A+quantitative+review&amp;author=K+Goodwin&amp;author=C+Viboud&amp;author=L+Simonsen&amp;volume=24&amp;publication_year=2006&amp;pages=1159-1169&amp;pmid=16213065&amp;doi=10.1016/j.vaccine.2005.08.105&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B16"><span class="citation">Gardner EM, Gonzalez EW, Nogusa S, Murasko DM. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. <span><span class="ref-journal">Vaccine. </span>2006;<span class="ref-vol">24</span>:1609\xe2\x80\x931614. doi: 10.1016/j.vaccine.2005.09.058.</span> [<a href="/pubmed/16260072" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2005.09.058" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Age-related+changes+in+the+immune+response+to+influenza+vaccination+in+a+racially+diverse,+healthy+elderly+population&amp;author=EM+Gardner&amp;author=EW+Gonzalez&amp;author=S+Nogusa&amp;author=DM+Murasko&amp;volume=24&amp;publication_year=2006&amp;pages=1609-1614&amp;pmid=16260072&amp;doi=10.1016/j.vaccine.2005.09.058&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B17"><span class="citation">Hsu LC, Lin SR, Hsu HM, Chao WH, Hsieh JT, Wang MC, Lu CF, Chang YH, Ho MS. Ethnic differences in immune responses to hepatitis B vaccine. <span><span class="ref-journal">Am J Epidemiol. </span>1996;<span class="ref-vol">143</span>:718\xe2\x80\x93724.</span> [<a href="/pubmed/8651234" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Epidemiol&amp;title=Ethnic+differences+in+immune+responses+to+hepatitis+B+vaccine&amp;author=LC+Hsu&amp;author=SR+Lin&amp;author=HM+Hsu&amp;author=WH+Chao&amp;author=JT+Hsieh&amp;volume=143&amp;publication_year=1996&amp;pages=718-724&amp;pmid=8651234&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B18"><span class="citation">Jianping H, Xin F, Changshun L, Bo Z, Linxiu G, Wei X, Jiande S. Assessment of effectiveness of Vaxigrip. <span><span class="ref-journal">Vaccine. </span>1999;<span class="ref-vol">17</span>:S57\xe2\x80\x9358. doi: 10.1016/S0264-410X(99)00107-3.</span> [<a href="/pubmed/10471182" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0264-410X(99)00107-3" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Assessment+of+effectiveness+of+Vaxigrip&amp;author=H+Jianping&amp;author=F+Xin&amp;author=L+Changshun&amp;author=Z+Bo&amp;author=G+Linxiu&amp;volume=17&amp;publication_year=1999&amp;pages=S57-58&amp;pmid=10471182&amp;doi=10.1016/S0264-410X(99)00107-3&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B19"><span class="citation">Hui SL, Chu LW, Peiris JSM, Chan KH, Chu D, Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. <span><span class="ref-journal">Vaccine. </span>2006;<span class="ref-vol">24</span>:5371\xe2\x80\x935380. doi: 10.1016/j.vaccine.2006.04.032.</span> [<a href="/pubmed/16713661" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2006.04.032" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Immune+response+to+influenza+vaccination+in+community-dwelling+Chinese+elderly+persons&amp;author=SL+Hui&amp;author=LW+Chu&amp;author=JSM+Peiris&amp;author=KH+Chan&amp;author=D+Chu&amp;volume=24&amp;publication_year=2006&amp;pages=5371-5380&amp;pmid=16713661&amp;doi=10.1016/j.vaccine.2006.04.032&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B20"><span class="citation">Wang C-S, Wang S-T, Lai C-T, Lin L-J, Chou P. Impact of influenza vaccination on major cause-specific mortality. <span><span class="ref-journal">Vaccine. </span>2007;<span class="ref-vol">25</span>:1196\xe2\x80\x931203. doi: 10.1016/j.vaccine.2006.10.015.</span> [<a href="/pubmed/17097773" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2006.10.015" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Impact+of+influenza+vaccination+on+major+cause-specific+mortality&amp;author=C-S+Wang&amp;author=S-T+Wang&amp;author=C-T+Lai&amp;author=L-J+Lin&amp;author=P+Chou&amp;volume=25&amp;publication_year=2007&amp;pages=1196-1203&amp;pmid=17097773&amp;doi=10.1016/j.vaccine.2006.10.015&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B21"><span class="citation">Li Q, Wang L-J, Wu H-Y, Song T. Rapid investigation of influenza-like cases incidence in Beijing urban area (2001) <span><span class="ref-journal">Chinese J Vaccines Immunization. </span>2003;<span class="ref-vol">5</span>:277\xe2\x80\x93279.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Chinese+J+Vaccines+Immunization&amp;title=Rapid+investigation+of+influenza-like+cases+incidence+in+Beijing+urban+area+(2001)&amp;author=Q+Li&amp;author=L-J+Wang&amp;author=H-Y+Wu&amp;author=T+Song&amp;volume=5&amp;publication_year=2003&amp;pages=277-279&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B22"><span class="citation">Kincannon CL, He W, West LA. Demography of aging in China and the United States and the economic well-being of their older populations. <span><span class="ref-journal">J Cross Cult Gerontol. </span>2005;<span class="ref-vol">20</span>:243\xe2\x80\x93255. doi: 10.1007/s10823-006-9015-1.</span> [<a href="/pubmed/17041789" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1007%2Fs10823-006-9015-1" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cross+Cult+Gerontol&amp;title=Demography+of+aging+in+China+and+the+United+States+and+the+economic+well-being+of+their+older+populations&amp;author=CL+Kincannon&amp;author=W+He&amp;author=LA+West&amp;volume=20&amp;publication_year=2005&amp;pages=243-255&amp;pmid=17041789&amp;doi=10.1007/s10823-006-9015-1&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B23"><span class="citation">Podda A, Del Giudice G, O\'Hagan DT.  MF59&#x02122;: a safe and potent adjuvant for human use. In: Schijns VEJC, O\'Hagan DT, editor. <span class="ref-journal">Immunopotentiators in modern vaccines.</span> Amsterdam: Academic Press; 2006. pp. 149\xe2\x80\x93159. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Immunopotentiators+in+modern+vaccines&amp;author=A+Podda&amp;author=G+Del+Giudice&amp;author=DT+O\'Hagan&amp;publication_year=2006&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B24"><span class="citation">Baldo V, Menegon T, Bonello C, Floreani A, Trivello R, Mariutto Collaborative Group  Comparison of three different influenza vaccines in institutionalised elderly. <span><span class="ref-journal">Vaccine. </span>2001;<span class="ref-vol">19</span>:3472\xe2\x80\x933475. doi: 10.1016/S0264-410X(01)00060-3.</span> [<a href="/pubmed/11348713" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0264-410X(01)00060-3" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Comparison+of+three+different+influenza+vaccines+in+institutionalised+elderly&amp;author=V+Baldo&amp;author=T+Menegon&amp;author=C+Bonello&amp;author=A+Floreani&amp;author=R+Trivello&amp;volume=19&amp;publication_year=2001&amp;pages=3472-3475&amp;pmid=11348713&amp;doi=10.1016/S0264-410X(01)00060-3&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B25"><span class="citation">Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. <span><span class="ref-journal">Vaccine. </span>2001;<span class="ref-vol">19</span>:2673\xe2\x80\x932680. doi: 10.1016/S0264-410X(00)00499-0.</span> [<a href="/pubmed/11257408" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0264-410X(00)00499-0" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=The+adjuvanted+influenza+vaccines+with+novel+adjuvants:+experience+with+the+MF59-adjuvanted+vaccine&amp;author=A+Podda&amp;volume=19&amp;publication_year=2001&amp;pages=2673-2680&amp;pmid=11257408&amp;doi=10.1016/S0264-410X(00)00499-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B26"><span class="citation">Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. <span><span class="ref-journal">Epidemiol Infect. </span>2005;<span class="ref-vol">133</span>:687\xe2\x80\x93693. doi: 10.1017/S0950268805003936.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2870297/">PMC free article</a>]</span> [<a href="/pubmed/16050515" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1017%2FS0950268805003936" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epidemiol+Infect&amp;title=Evidence+of+increased+clinical+protection+of+an+MF59-adjuvant+influenza+vaccine+compared+to+a+non-adjuvant+vaccine+among+elderly+residents+of+long-term+care+facilities+in+Italy&amp;author=A+Iob&amp;author=G+Brianti&amp;author=E+Zamparo&amp;author=T+Gallo&amp;volume=133&amp;publication_year=2005&amp;pages=687-693&amp;pmid=16050515&amp;doi=10.1017/S0950268805003936&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B27"><span class="citation">Banzhoff A, Nacci P, Podda A. A new MF59&#x02122;-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. <span><span class="ref-journal">Gerontology. </span>2003;<span class="ref-vol">49</span>:177\xe2\x80\x93184. doi: 10.1159/000069172.</span> [<a href="/pubmed/12679609" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1159%2F000069172" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gerontology&amp;title=A+new+MF59&#x02122;-adjuvanted+influenza+vaccine+enhances+the+immune+response+in+the+elderly+with+chronic+diseases:+results+from+an+immunogenicity+meta-analysis&amp;author=A+Banzhoff&amp;author=P+Nacci&amp;author=A+Podda&amp;volume=49&amp;publication_year=2003&amp;pages=177-184&amp;pmid=12679609&amp;doi=10.1159/000069172&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B28"><span class="citation">De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A. Safety and immunogenicity of MF59&#x02122;-adjuvanted influenza vaccine in the elderly. <span><span class="ref-journal">Vaccine. </span>1999;<span class="ref-vol">17</span>:3094\xe2\x80\x933101. doi: 10.1016/S0264-410X(99)00138-3.</span> [<a href="/pubmed/10462245" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0264-410X(99)00138-3" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Safety+and+immunogenicity+of+MF59&#x02122;-adjuvanted+influenza+vaccine+in+the+elderly&amp;author=S+De+Donato&amp;author=D+Granoff&amp;author=M+Minutello&amp;author=G+Lecchi&amp;author=M+Faccini&amp;volume=17&amp;publication_year=1999&amp;pages=3094-3101&amp;pmid=10462245&amp;doi=10.1016/S0264-410X(99)00138-3&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B29"><span class="citation">Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A. An MF59&#x02122;-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. <span><span class="ref-journal">Vaccine. </span>2006;<span class="ref-vol">24</span>:3063\xe2\x80\x933065. doi: 10.1016/j.vaccine.2006.01.015.</span> [<a href="/pubmed/16464520" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2006.01.015" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=An+MF59&#x02122;-adjuvanted+inactivated+influenza+vaccine+containing+A/Panama/1999+(H3N2)+induced+broader+serological+protection+against+heterovariant+influenza+virus+strain+A/Fujian/2002+than+a+subunit+and+a+split+influenza+vaccine&amp;author=G+Del+Giudice&amp;author=AK+Hilbert&amp;author=R+Bugarini&amp;author=A+Minutello&amp;author=O+Popova&amp;volume=24&amp;publication_year=2006&amp;pages=3063-3065&amp;pmid=16464520&amp;doi=10.1016/j.vaccine.2006.01.015&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B30"><span class="citation">Puig-Barber&#x000e0; J, Diez-Domingo J, Hoyos SP, Varea AB, Vidal DG. Effectiveness of the MF59&#x02122;-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. <span><span class="ref-journal">Vaccine. </span>2004;<span class="ref-vol">23</span>:283\xe2\x80\x93289. doi: 10.1016/j.vaccine.2004.07.017.</span> [<a href="/pubmed/15530669" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2004.07.017" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Effectiveness+of+the+MF59&#x02122;-adjuvanted+influenza+vaccine+in+preventing+emergency+admissions+for+pneumonia+in+the+elderly+over+64+years+of+age&amp;author=J+Puig-Barber&#x000e0;&amp;author=J+Diez-Domingo&amp;author=SP+Hoyos&amp;author=AB+Varea&amp;author=DG+Vidal&amp;volume=23&amp;publication_year=2004&amp;pages=283-289&amp;pmid=15530669&amp;doi=10.1016/j.vaccine.2004.07.017&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B31"><span class="citation">Puig-Barber&#x000e0; J, D&#x000ed;ez-Domingo J, Varea AB, Chavarri GS, Rodrigo JAL, P&#x000e9;rez-Hoyos S, Vidal DG. Effectiveness of MF59&#x02122;-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. <span><span class="ref-journal">Vaccine. </span>2007;<span class="ref-vol">25</span>:7313\xe2\x80\x937321. doi: 10.1016/j.vaccine.2007.08.039.</span> [<a href="/pubmed/17889411" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.vaccine.2007.08.039" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Effectiveness+of+MF59&#x02122;-adjuvanted+subunit+influenza+vaccine+in+preventing+hospitalisations+for+cardiovascular+disease,+cerebrovascular+disease+and+pneumonia+in+the+elderly&amp;author=J+Puig-Barber&#x000e0;&amp;author=J+D&#x000ed;ez-Domingo&amp;author=AB+Varea&amp;author=GS+Chavarri&amp;author=JAL+Rodrigo&amp;volume=25&amp;publication_year=2007&amp;pages=7313-7321&amp;pmid=17889411&amp;doi=10.1016/j.vaccine.2007.08.039&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B32"><span class="citation">O\'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. <span><span class="ref-journal">Expert Rev Vaccines. </span>2007;<span class="ref-vol">6</span>:699\xe2\x80\x93710. doi: 10.1586/14760584.6.5.699.</span> [<a href="/pubmed/17931151" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1586%2F14760584.6.5.699" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Vaccines&amp;title=MF59+is+a+safe+and+potent+vaccine+adjuvant+that+enhances+protection+against+influenza+virus+infection&amp;author=DT+O\'Hagan&amp;volume=6&amp;publication_year=2007&amp;pages=699-710&amp;pmid=17931151&amp;doi=10.1586/14760584.6.5.699&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="B33"><span class="citation">D\'Agosto V, Berardi S, Burroni D, Hennig R. Tolerability and safety of an MF59-adjuvanted subunit influenza vaccine (FLUAD<sup>&#x000ae;</sup>) <span class="ref-journal">Poster presented at the 2nd International Conference on Influenza Vaccines for the World (IVW), Vienna, Austria.</span>  18&#x02013;20 October 2006.</span></li><li id="B34"><span class="citation">Committee for Proprietary Medicinal Products (CPMP)  Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 12 March 1997 <a href="http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf</a> accessed November 2007.</span></li><li id="B35"><span class="citation">Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. <span><span class="ref-journal">Br Med Bull. </span>1979;<span class="ref-vol">35</span>:69\xe2\x80\x9375.</span> [<a href="/pubmed/367490" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+Med+Bull&amp;title=Determinants+of+immunity+to+influenza+infection+in+man&amp;author=CW+Potter&amp;author=JS+Oxford&amp;volume=35&amp;publication_year=1979&amp;pages=69-75&amp;pmid=367490&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2291031&amp;issue-id=162315&amp;journal-id=287&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li></ul></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">Immunity &#x0026; Ageing : I &#x0026; A</span> are provided here courtesy of <strong>BioMed Central</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2291031/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2291031/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2291031/pdf/1742-4933-5-2.pdf">PDF (484K)</a></li> | <li><a href="#" data-citationid="PMC2291031" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2291031%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2291031%2F&amp;text=Safety%20and%20immunogenicity%20of%20an%20MF59%E2%84%A2-adjuvanted%20subunit%20influenza%20vaccine%20in%20elderly%20Chinese%20subjects"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2291031%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="18289372" data-aiid="2291031" data-aid="2291031" data-iid="162315" data-domainid="287" data-domain="immage" data-accid="PMC2291031" data-md5="d003f3e4095a0d511037eac249d2ba13"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T09:40:29-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc101&amp;ncbi_phid=8A1A1C49E99AEEA10000000001EB01EB&amp;ncbi_session=8A1A1C49E99B1CD1_0491SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2291031%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=immage&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2291031/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1A1C49E99B1CD1_0491SID /projects/PMC/PMCViewer@4.46 ptpmc101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'